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in Advanced Chronic Kidney Disease*Charles A. Herzog, MD,yz Gautam R. Shroff, MBBSySEE PAGES 703 AND 715P atients with advanced chronic kidney disease(CKD), including end-stage renal disease(ESRD), represent both an enigma and a chal-
lenge to cardiovascular specialists. A gradient of
increasing hazard of all-cause mortality with ad-
vancing degrees of CKD is well recognized. Reported
adjusted mortality rates (per 1,000 patient-years) for
patients 65 years of age and older are 64, 109, and
266, respectively, for those with stage 3 CKD, with
stage 4 to 5 CKD, and undergoing dialysis (vs. 54
for patients without CKD) (1). The largest contributor
to increased morbidity and mortality in patients
with advanced CKD or ESRD is a disproportionately
high cardiovascular disease (CVD) burden (Figs. 1A
and 1B). Less well recognized is that the factors
contributing to increased CVD mortality transition
from atherosclerotic causes in advanced CKD
(a largely older population) to nonatherosclerotic
causes in ESRD (Fig. 2). Arrhythmias and sudden
cardiac death (SCD) account for 27% of all deaths
(62% of cardiovascular deaths) among dialysis re-
cipients; annual mortality rates of 5% to 7% are
attributed to SCD alone, likely related to nonathero-
sclerotic mechanisms, such as left ventricular (LV)
hypertrophy and myocardial ﬁbrosis (2). Hakeem
et al. (3) provide strong support for the importance
of nonatherosclerotic mechanisms of cardiac death
(rather than obstructive coronary artery disease
[CAD]) in patients with advanced CKD. Patients* Editorials published in JACC: Cardiovascular Imaging reﬂect the views
of the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
From the yDivision of Cardiology, Department of Medicine, Hennepin
County Medical Center and University of Minnesota, Minneapolis, Min-
nesota; and the zChronic Disease Research Group, Minnesota Medical
Research Foundation, Minneapolis, Minnesota. Both authors have re-
ported that they have no relationships relevant to the contents of this
paper to disclose.with entirely normal myocardial perfusion single-
photon emission computed tomographic studies had
annual cardiac death rates of 0.4% for an estimated
glomerular ﬁltration rate (eGFR) of 90 ml/min/1.73
m2, 0.9% for an eGFR of 60 to 89 ml/min/1.73 m2,
2.2% for an eGFR of 30 to 59 ml/min/1.73 m2, and
4.7% for an eGFR <30 ml/min/1.73 m2. Although it
is tempting to ascribe these ﬁndings to the dimin-
ished sensitivity of stress nuclear imaging for detec-
tion of obstructive CAD in patients with severe
CKD (4), the authors of this editorial believe that
the key issue these data present (concordant with
the attenuation of beneﬁt found in randomized clin-
ical trials of statins in dialysis recipients) is the
large mortality hazard due to nonatherosclerotic
disease in patients with advanced CKD, and espe-
cially those requiring dialysis.Imaging modalities offer tremendous potential to
improve understanding of this continuum of high
CVD burden in advanced CKD, as discussed in 2 re-
view papers in this issue of iJACC. Edwards et al.
(5) make a compelling argument for considering
cardiac magnetic resonance (CMR) as the gold stan-
dard for evaluating “uremic” cardiomyopathy. The
descriptors leading to current understanding of ure-
mic cardiomyopathy (probably more accurately
designated as “cardiomyopathy of CKD”) have been
mainly derived using transthoracic echocardiogra-
phy. These investigators (5) illustrate several advan-
tages of CMR over transthoracic echocardiography,
including better spatial resolution for estimation of
LV mass and more accurate estimation of LV and
right ventricular systolic function, but most impor-
tantly, they offer insights into the etiopathogenesis
of cardiomyopathy by using tissue characterization.
AB
FIGURE 1 Morbidity and Mortality in Patients With CKD or ESRD
(A) Cardiovascular disease burden in Medicare patients 66 years of age and
older with and without chronic kidney disease (CKD). (B) Causes of death
among prevalent dialysis recipients in the United States, 2009 to 2011.
AMI ¼ acute myocardial infarction; CHF ¼ congestive heart failure; CVA ¼
cerebrovascular accident; ESRD ¼ end-stage renal disease; TIA ¼ transient
ischemic attack. Adapted from U.S. Renal Data System (1).
FIGURE 2 Cardiovascular Disease Burden in Advancing CKD
A conceptual framework of contributors to the cardiovascular
disease burden in patients with advancing CKD. Abbreviations as
in Figure 1.
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730Safe and accurate illustration of myocardial ﬁbrosis
promises to be the Rosetta Stone for deciphering the
mystery of SCD in ESRD. Before the description of
nephrogenic systemic ﬁbrosis, 2 trends were evident
in the literature pertaining to patterns of late gado-
linium enhancement (LGE): 1) a higher volume of LGE
was described among patients with progressively
worsening CKD (associating with increasing LV
mass); and 2) several distinctive patterns of LGE were
noted, of which only a minority were related to
infarction and the others were probably indicators of
an inﬂammatory state. For clinicians, the obvious
missing element from these smaller, cross-sectional
studies is a systematic, prospective correlation of
these LGE patterns with adverse clinical outcomes,
particularly SCD.
The implication of gadolinium in the development
of nephrogenic systemic ﬁbrosis, a rare but devas-
tating disease, has proven thus far to be a formidablebarrier to further research in this area. Meanwhile,
provocative clinical work has identiﬁed systemic
inﬂammation, vascular inﬂammation, endothelial
dysfunction, and myocardial ﬁbrosis as possibly
playing central roles in the high rates of SCD among
patients with ESRD. The most recent example is a
small but promising randomized trial in 309 hemo-
dialysis recipients that was reported by Matsumoto
et al. (6); it, showing that aldosterone blockade with
low-dose spironolactone led to reductions in cardio-
vascular events and all-cause mortality. Because hy-
pokalemia has been implicated in the pathogenesis of
SCD in patients with ESRD, a possible confounder is
that the “potassium-sparing” effect of spironolactone
may itself have played a signiﬁcant role. In the im-
aging arena, T1 mapping using CMR has shown
promise in ﬁbrosis evaluation by offering the distinct
advantage of intrinsic tissue characterization in the
absence of gadolinium-based contrast. Several tech-
nical wrinkles are being ironed out (7), and even
though this technique may not yet be ready for uni-
versal use, the authors of this editorial hope that its
use can be expanded to the population with ESRD in
the near future. Most ideally, multimodality imaging
(including CMR) would be prospectively incorpo-
rated into clinical trials such as the WED-HED
(Wearable Cardioverter Deﬁbrillator in Hemodialysis
Patients) study, which is designed to evaluate the
beneﬁt of wearable external deﬁbrillators in pre-
venting SCD in hemodialysis recipients.
Also in this issue of iJACC, Hakeem et al. (8) tackle
the vexing issue of “screening” for CAD, particularly
risk assessment before renal transplantation. The
existing literature is particularly confusing because it
reports on a potpourri of imaging modalities without
a consistent gold standard or rigorous clinical
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731endpoints. Central to this confusion are disagree-
ments among premier institutions regarding the
pursuit of “ischemia-based” evaluation (noninvasive
risk stratiﬁcation) versus “structural” evaluation
(direct coronary angiography). Considering the large
number of renal transplants performed worldwide
and the 5-fold higher numbers of patients on waiting
lists (17,671 transplants and 90,474 wait-listed pa-
tients in the United States in 2011), it is certainly not a
matter of pride for the medical community that this
subject has not been more systematically and delib-
erately addressed to date. In fact, the basic premise
that screening for CAD and resultant prophylactic
revascularization in asymptomatic patients with
advanced CKD leads to improved post-operative and
long-term outcomes has not yet been adequately
tested. Importantly, this premise was tested and
proven incorrect in the general population.
Several centers rely on cardiovascular biomarkers,
particularly high-sensitivity troponins, to detect
high-risk substrate (predictive of higher probability
of short- and long-term mortality), rather than
merely identifying obstructive CAD alone; this
approach appears to be more plausible, on theFIGURE 3 Diagnosing CAD in Renal Transplant Candidates
Receiver-operating characteristic (ROC) curves for diagnosing coronary
with permission from Wang et al. (4). Copyright ª 2011 The Cochrane Cbasis of our knowledge of the high incidence of non-
atherosclerotic causes of death among patients with
ESRD. Another noteworthy limitation in the literature
is the lack of validation data pertaining to the use of
fractional ﬂow reserve estimation in patients with
ESRD and its predictive role in estimating long-term
outcomes. Conceivably, lack of fractional ﬂow
reserve use in centers adopting a “direct” coronary
angiography technique relying on qualitative estima-
tion of CAD alone could result in “unnecessary” cor-
onary revascularization procedures. Thus, overall, the
authors of this editorial contend that an “ischemia-
based” strategy is a more conservative intermediate
step that can help direct the need for, and identify
territories for, coronary revascularization while
simultaneously obviating the costs and risks (includ-
ing contrast nephropathy) of an invasive approach in
most patients. This critical clinical issue will be
addressed by the ISCHEMIA-CKD trial (NCT01985360).
In this quest to identify the most accurate
noninvasive diagnostic modality in an “ischemia-
based” strategy, 1 notable study that is conspicuous
by its absence in the review by Hakeem et al. (8) is a
meta-analysis by Wang et al. (4). Using a hierarchicalartery disease (CAD) in renal transplant candidates. Adapted
ollaboration. Published by John Wiley & Sons, Ltd.
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732modeling strategy, Wang et al. (4) reported pooled
sensitivity and speciﬁcity estimates, respectively, of
0.79 and 0.89 for dobutamine stress echocardiogra-
phy (13 studies) and of 0.74 and 0.70 for myocardial
perfusion imaging (9 studies); Figure 3 shows the
receiver-operating characteristic curves. Dobutamine
stress echocardiography was found to be more ac-
curate than myocardial perfusion imaging (p ¼ 0.02)
when all studies were included; this difference was
not evident when studies not using a standard
reference for obstructive CAD $70% stenosis were
excluded (p ¼ 0.09). Factors hypothesized to explain
the reduced accuracy of myocardial perfusion im-
aging include reduced coronary ﬂow reserve in the
context of LV hypertrophy, endothelial dysfunction,
the possibility of “balanced ischemia,” and greater
interobserver variability. The algorithm proposed by
Hakeem et al. (8) is based on an approach extrapo-
lated from the general population, not hitherto
supported by evidence pertaining to patients withESRD. We urge caution in implementing this ap-
proach, which could be viewed as overly simplistic,
in this population.
In conclusion, an expanded diagnostic armamen-
tarium in the contemporary era, including multiple
complementary imaging modalities, can guide
appropriate diagnostic and therapeutic evaluation of
patients with advanced CKD or ESRD. The challenge
for cardiovascular imaging specialists is to acquire
ﬂuency in the interpretation of these techniques, in
the context of an accurate pre-test probability
knowledge, to ensure that the appropriate research
questions are asked and the appropriate clinical
questions are answered.
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